of morning all good you and Chris, to us you, joining Thank today.
our take XXXX. and for financial for financial will results XXXX as We through plans well as our you and accomplishments guidance
challenging us, to and while our our We many of having especially our and of shareholders. to be on a I'm colleagues themselves of for customers on doing Slide responsible business, environment. from the all right delivering proud patients, turn our X. stewards environment. commitments our by financial to Please supply and remain focused economic was for of year XXXX the demonstrated macro challenges
our exceeded advanced growth and full capabilities. met strategic initiatives our key organic original bolstered our guidance, adjusted We targets, year EPS
XXXX, So let M&A new me portfolio, start product introductions, by for highlighting that in to optimization but expanded also strategic capabilities several commercial not only growth. our these including key accomplishments our strengthened capitalize of and
Specialty portfolio extensions a we important recent line In launch with added our tip and QX. CUSA of with our our laparoscopic to division, Surgical tip, Codman in late bone clearance
it's from these will technology be a the revenues this differentiation XXXX they new our enhance of that Although modest, with illustrate contribution to direct product CUSA utility in our of line continued functionalities platform. products
address we coagulation We to tip also partner continue plus as with the U.S in platform. surgeons and launched Aurora expands the the Evacuator Aurora to their needs
mid In launched NeuraGen nerve our a unique Tissue division, we product. cap XD, Technologies repair
the successfully through We of completed team. of our sales the also reconstruction the wound expansion integration portfolio ACell
growth in portfolio the planned to we year ACell the As ago, returned half grew a digits of second XXXX. double and
remain on Now integrated business, we our progress with earnings we during We last and Conference. SurgiMend wound discussed track for our Health that the breast on well-positioned our deliver JPMorgan at the expectations the business. Cytal PMA and MicroMatrix, and of approval implant strong on care into use based the recent in for Care made growth we Gentrix to sales are that substantial long-term and for fully are reconstruction timeline call,
will In reconstruction growth resorbable strengthen innovative or we high mesh. breast strategy DuraSorb, Associates synthetic December, Surgical an the acquired of makers market. for SIA, Innovation our DuraSorb The
needs by distinct contracting by addressing offering and to the economic two of markets. various and DuraSorb with SurgiMend, sites leading product the products path and plastic securing a Now build and PMA clinical reconstructive a to Integra different And solutions care. we surgeons, second first can in across have position
divisional connection our that and first the with contribute for market product we to With in M&A gameboard, strategies. roadmaps strategy. M&A how out we’ve clear of completed where our our laid new deal which growth gameboard, will our reviews from came was our SIA in-depth
our or last Finally, with third on regenerative in in quarter non-core or business TWC, care line year. differentiated the divested focus of wound traditional technologies, we
commercial to profitability [ph] our organization. capabilities France we continued manufacturing high-cost listening closed and our strategic resources properties, enabled And portfolio to out redeploy to us which facility back-office imperatives. and select We and to build in outsourced and our a operations increase activities, and
first first key as is heading our executive as Officer executive Harvinder the well organization Singh, our Mark U.S. of leadership outside located company's with up VP International and additions, is strengthened We including the Chief appointments Jesser, who Digital Business
within and ambition the efficiency. We also particularly broadly, more talents marketing, manufacturing with innovation strengthen operational our capabilities to our strategic added quality organizations and
across organization, We inclusion the organization. engagement development on invest and continue our in up stepping potential further to of focused maximize talent the to
shareholders. Within when We year last in saving have life our formalized inaugural roadmap to deliver we our sustainability culture, ESG sustainability embraced we our technologies to a our we guiding returns reports. and as and principle produce patients while financial how issued providing surgeons
Our commitment again Integra year was out to the and dispositions as and belief being great organizations we several for external a lot for culture work. recognizing XXXX called well for to place Clearly beyond. our once by accomplished a
our performance. I Despite to through X for these environment, year. the proud delivered stated hurdles for challenging of as before, solid And now of turn navigating I'm skillfully XXXX in with Let's colleagues the the Slide XXXX. results our highlights we financial
approximately unfavorable $X.XX or the basis, and compared of Our full million to divestiture, year last revenues $XX reported from foreign points inclusive X% basis TWC were on exchange year. XXX impact growth a billion,
We X.X% the year. delivered organic growth for
provides X.X%, diverse our Throughout consistent demand we business and year, saw across growth the the of portfolio. mitigate recovery of the markets year and the a levels. strength demonstrating our CereLink procedures solid ended in the we relaunch pre-COVID This for Excluding prepare our XXXX near second of CereLink, at of approximately further was organic remainder by challenges quarter. end foundation the for the as supply
to FX X.X%. per strategic representing of while earnings CereLink headwinds recall well invest of half EBITDA XX year range. continuing impacts. We as by Full our margin second in adjusted as $X.XX, the higher-than-expected above and our both share growth key operations growth delivered increased basis priorities. our We both overcame February guidance points, We
cash also million XX% the cash solid year for conversion. in We operating with cash and free flow delivered flows $XXX flow
impact to for reported prior unfavorable we insights divestiture. million, turn X fourth revenue total decrease into the to our On FX of of $XXX inclusive year. Slide performance. impact a an additional and now were a organic representing quarter Please the $XX delivered compared growth TWC Fourth the X.X% quarter, on revenues X.X% from basis, the of million basis,
key across double-digit growth ACell. demand solid saw segments product we from including Overall, recovery our lines, and various
business by tempered private CereLink challenges, our and across growth the in recall label the was quarter However, orders. supply of normalization
revenue year. to If revenues X.X% on an prior organic highlights deeper the Slide the Reported take fourth into quarter our for dive a you CSS from turn CSS fourth increase in basis were $XXX quarter. X, million, of we'll an
Excluding CereLink led growth organic remaining and parts portfolio, across energy the was product of X.X% lines. CSS management by advanced CSF
availability, and of access down were monitoring Then driven growth declined low low neuro capital sales. single management single-digit to a Advanced sales double result supply CUSA in low and driven grew X.X%. Neurosurgery our CSS by digits that material digits repair and by capital mid-single-digits Global up was valves. including Dural small packaging energy challenges, due CereLink. as programmable grew
single international with growth Sales digits China with indirect our sales of coming expectations Instruments increased And low mid-single-digit CSS grew this markets. from our franchise. and line in digits long-term low for in single Japan, growth
the compared basis to X. on from our PriMatrix, increase a an Slide Technologies solid Reconstruction an X.X% portfolio, were X% organic Skin, by Tissue Tissue XXXX, Moving Cytal. on to Tech sales in basis segment performance grew on Wound prior the led organic of and QX across Reported million, an MicroMatrix Integra $XXX year.
capacity in quarter of momentum and the finalized for combined We're double-digit sales team. delivering ACell and productivity the as of and the growth benefited pleased integration with year the half the ACell the the from of we accelerated of second increased
in down label X% Sales for quarter to the compared private XXXX. were
may double-digit safety increased as the difficulty] saw year half our the [technical their through You supply private that recall label of growth first partners chains. in to stocks their we
normalize, in begin these levels year. lower seen versus inventory sales We have prior the to since resulting
Turning QX supply gross quarter inflation. And year. the compared gross to from expected Slide XX margin points than basis will for saw I full fourth our P&L some impacted products. in down and the we chain more Adjusted the challenges as our recall impacts XX. XX.X% highlights XXXX, the of was higher to margin also cover CereLink and of the
points. Our carefully We the investments significant costs QX operating in basis expenses our drivers. growth to redeploying key adjusted managed XX% compared XX.X% of overhead EBITDA margin by strategic and improvement XXX restructuring prior to our in was year,
by improve management disciplined full our to allowed basis spending year XX Our points. adjusted EBITDA margin us
versus were quarter fourth the for share per $X.XX, XXXX. $X.XX earnings up Adjusted
and CereLink above high-end spending allowed careful well by Our full also full to adjusted FX the full to EPS the deliver our year headwinds year enabled as EPS year as X.X%. The guidance. us original grew us offset of recall
If a was and cash $XXX a turn flow cash cash cash flow conversion. XX sheet million to quarter XX% items. on full in you our year basis, free cash Slide Operating balance and was flow free million. update cash $XX brief $XXX flow was $XX free and million; flow million for the operating with On
available million of As including billion total $X -- revolving under company total and credit Xx. X.Xx to under in revolving target ratio of the and December range our X.Xx, was approximately liquidity of below was facility. remainder debt XX, The cash billion, our net leverage $XXX our had $X.XX
of down million additional executed the share With beginning shareholders repurchase the been able strong commenced to share a XXXX repurchase in as and $XXX cash value return $XXX XXXX. debt and million to flow, we’ve we at pay
and let to With us, What to stepped growth, accretion Slide XXXX is future drive growth. margin and in will strengthened a of up initiatives go support to acceleration behind further investment Integra XXXX XX. turn us strategic XXXX in now
side, solid for as providing we procedures earlier, XXXX. levels, I us pre-COVID the with a in the On growth near revenue year exited mentioned foundation
components with reflects this procedural supply, outlook reliability gradual sourcing along demand, of including of and improvement a packaging. Our
the We at products the end relaunching of to excited also for grow, second of expect are overall we at prospect and further demand quarter. the CereLink our
to DuraSorb, favorable growth, with along on from products are expected and growth mix, drive Our our product offering XXXX efficiencies most recent strong in manufacturing profitable increased price focus contribute driven margin to our acquisition. new the to improvements We SIA, capture within by gross company's sites. intend with the
our of our the of benefit TWC impact cost France. year divestiture will We from closure in high also the manufacturing and site full
approval stepping investments delivery growth, and advancements of and These further readiness strong accelerators generation mean in to manufacturing growth. capabilities relevant our that include: DuraSorb, SurgiMend platform; preparation regulatory our strategic will With key for future of well ourselves submissions and studies, our [indiscernible]. PMA on the lastly, evidence core profitable clinical and position execution PMA-level our sites for business reinvest we first, second, by of our strengthening up which of I of products; and enhanced reimbursement produce our to the Aurora portfolio PMA clinical to support and growth
in international invest the our first also our pilots. will and business digital of We expansion
Slide to translate drivers XXXX. financial to XX Turning expectations into these for
to growth of $X.XXX reported For of revenues the X.X%. we the to X.X% full of organic to be range year, $X.XXX growth billion X% to expect representing and of billion, in X%
Our reflects of revenue FX, versus few over the points currencies a compared lower strengthening impact U.S. the the for the result which from past accounts dollars range months. XX as basis headwind major foreign XXXX of to
of result in If to the in half of compared year year contribution a expect timing of detail number growth revenue, mainly as second we the year first we higher half a of full more items. the look to the XXXX at see
First, expect the year. in second improvement more as half will gradual to contribute heavily previously, the which we supply, mentioned a
Next, CereLink second on we the XXXX,and quarter of of quarter relaunching have recall the the of we anticipate year-over-year at impact the XXXX. end third
China the label continue a year. of normalize end the comps from expect Third, second given lockdowns our in half contribution the private year. lastly, in we resulting larger we the half, to XXXX, first of tougher rolling And in last to in late expect business
from of the X the organic in basis, at guidance, in see a midpoint first of create first will XXXX. half X% reported months second the expect Overall, of TWC approximately half unfavorable comp the divestiture of approximately an the to growth you On we and XXXX. timing X% in
of year, Turning to range $X.XX outlook the earnings our adjusted be we profit for to$X.XX. per expect share the to in
to of If for XX look quarter at turn guidance for first a you Slide XXXX. the our
of to representing the and of we X% million, $XXX quarter, to expect range growth $XXX be first revenues million approximately of X.X%. in X.X% to reported negative flat growth the to organic For
by We expect quarter first impacted most the I year-over-year comps the before. to highlighted be
the $X.XX, Turning flat range to guidance. quarter for adjusted midpoint first to adjusted earnings be expect XXXX, year-over-year guidance EPS the the we of $X.XX at in of to the
you summary at pillars our look prepared turn conclude with Slide If to XX, of I the strategic remarks. a will brief and our
from business five earlier outlined beyond. strategic we've XXXX we this As rolled pillars and around year, the
catching The first are culture. The our and growth our high-performance therapeutic care across on three impact the we key international customer driving innovation growth levers, a the focus. in pillars outcomes, driving broadening operations stronger biggest and in up for cultivating enablers: is areas which last and our potential two excellence pillars on pathways
These our Day. our we're going strategy we will XXXX our five prioritizing forward and at understand how plan. how Investor to long-range our execute where pillars are X a look achieve and building to great results investments our to and towards We deeper into way May
of with markets remarks. portfolio full year resilient was the operating XXXX, delivered organic the Slide move still and we let's In to We brands. were diverse last now to and about in So X% on our tough a what conclude global products to growth recovering prepared able capitalize environment. great slide, our the for XX
a Our growth XXXX plan. points organic of execution the of path in our within range towards clear long-range
profitability in Utilizing for a to of in to implant-based set delivered repurchases, the one restructuring the expected we operating year, of position levers, exceeded management, the focused markets more reconstruction. additional our operational most strategic commitment our exciting of and share shareholders efficiencies, form price portfolio and value a growth careful a strengthen capture, breast including cost acquisition we and broad
in positioned gross to organic our growth beyond XXXX and are rates improve our and We margins. accelerate
growth our will which our temper redeployed portion a of and EBITDA to in EPS For margin growth. will investments catalysts, improvement be XXXX, that
enable and investments will core deliver capabilities to and our meet these while to our us to products However, develop and plan technologies resilience strengthen for our building operational further the capability long-range life-saving customers, targets. fuel
and So to I for us to Aussermeier going prepared the back the Mathieu And and that Chris? Mosebrook the will brings join hand Chris operator. to end it the remarks. Q&A. Jeff now me of
